loading
Revelation Biosciences Inc stock is traded at $0.76, with a volume of 23,693. It is up +0.53% in the last 24 hours and down -15.57% over the past month. Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$0.7588
Open:
$0.7936
24h Volume:
23,693
Relative Volume:
0.01
Market Cap:
$3.22M
Revenue:
-
Net Income/Loss:
$-120.30K
P/E Ratio:
-1.3816
EPS:
-0.5501
Net Cash Flow:
$-7.29M
1W Performance:
-8.82%
1M Performance:
-15.57%
6M Performance:
-61.16%
1Y Performance:
-96.03%
1-Day Range:
Value
$0.7571
$0.7936
1-Week Range:
Value
$0.7154
$0.84
52-Week Range:
Value
$0.702
$25.26

Revelation Biosciences Inc Stock (REVB) Company Profile

Name
Name
Revelation Biosciences Inc
Name
Phone
650-800-3717
Name
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Name
Employee
9
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
REVB's Discussions on Twitter

Compare REVB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
REVB 0.76 3.22M 0 -120.30K -7.29M -0.5501
VRTX 446.52 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.51 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.50 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.90 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.19 24.49B 3.30B -501.07M 1.03B 11.54

Revelation Biosciences Inc Stock (REVB) Latest News

pulisher
Nov 20, 2024

Warning: REVB is at high risk of performing badly - MSN

Nov 20, 2024
pulisher
Nov 12, 2024

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart

Nov 11, 2024
pulisher
Nov 11, 2024

REVB: Good Expense Control as Company Prepares for Trials - Research Tree

Nov 11, 2024
pulisher
Nov 11, 2024

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Nov 11, 2024
pulisher
Nov 11, 2024

Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

REVB Results Set Stage for Future Growth - Yahoo Finance

Nov 11, 2024
pulisher
Nov 08, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 08, 2024

Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy

Nov 08, 2024
pulisher
Oct 27, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN

Oct 27, 2024
pulisher
Oct 21, 2024

Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India

Oct 21, 2024
pulisher
Oct 03, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN

Oct 03, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Sep 25, 2024

A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar

Sep 24, 2024
pulisher
Sep 24, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha

Sep 23, 2024
pulisher
Sep 21, 2024

Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India

Sep 21, 2024
pulisher
Sep 21, 2024

Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia

Sep 21, 2024
pulisher
Sep 18, 2024

Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines CFO sells over $99k in company stock - Investing.com India

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines executive sells over $200k in company stock - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK

Sep 18, 2024
pulisher
Sep 17, 2024

Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire

Sep 17, 2024
pulisher
Sep 17, 2024

455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat

Sep 17, 2024
pulisher
Sep 16, 2024

Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - Seeking Alpha

Sep 16, 2024
pulisher
Sep 13, 2024

RVLV stock soars to 52-week high, touches $24.67 - Investing.com

Sep 13, 2024
pulisher
Sep 02, 2024

Financial Metrics Check: Revelation Biosciences Inc (REVB)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 02, 2024
pulisher
Aug 30, 2024

United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN

Aug 30, 2024
pulisher
Aug 26, 2024

Revelation Biosciences announces warrant exercise and inducement - Investing.com India

Aug 26, 2024
pulisher
Aug 25, 2024

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Manchestertimes

Aug 25, 2024
pulisher
Aug 23, 2024

Stock Performance Spotlight: Revelation Biosciences Inc (REVB) Ends the Day at 1.25, Down by -40.19 - The Dwinnex

Aug 23, 2024
pulisher
Aug 22, 2024

Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results - Benzinga

Aug 22, 2024
pulisher
Aug 22, 2024

Gold Down Over 1%; US Initial Jobless Claims Increase - Benzinga

Aug 22, 2024

Revelation Biosciences Inc Stock (REVB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):